ARCA biopharma (ARCA biopharma) EBIT : $-7.98 Mil (TTM As of Mar. 2024)

View and export this data going back to 1997. Start your Free Trial

What is ARCA biopharma EBIT?

ARCA biopharma's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-2.48 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-7.98 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. ARCA biopharma's annualized ROC % for the quarter that ended in Mar. 2024 was -4,060.53%. ARCA biopharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -7,066.19%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. ARCA biopharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -54.35%.

ARCA biopharma EBIT Historical Data

The historical data trend for ARCA biopharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARCA biopharma EBIT Chart

ARCA biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-5.64

-9.74

-19.34

-10.60

-7.30

ARCA biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-1.80	-1.97	-1.94	-1.59	-2.48

Competitive Comparison of ARCA biopharma's EBIT

For the Biotechnology subindustry, ARCA biopharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ARCA biopharma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ARCA biopharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ARCA biopharma's EV-to-EBIT falls into.

ARCA biopharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.98 Mil.

ARCA biopharma (NAS:ABIO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

ARCA biopharma's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-9.928 * ( 1 - 0% )	/	( (0.369	+	0.12)	/ 2 )
=	-9.928	/	0.2445
=	-4,060.53 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	37.861	-	0.537	-	( 37.431	-	max(0, 0.637	-	37.592	+	37.431	))
=	0.369

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	36.706	-	1.497	-	( 35.903	-	max(0, 1.581	-	36.67	+	35.903	))
=	0.12

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

ARCA biopharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-9.928	/	( ( (0.257 + max(-0.476, 0))	+	(0.024 + max(-0.814, 0)) )	/	2 )
=	-9.928	/	( ( 0.257	+	0.024 )	/	2 )
=	-9.928	/	0.1405
=	-7,066.19 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.161)	-	(0.537	+	0	+	0.1)
=	-0.476

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.767)	-	(1.497	+	0	+	0.084)
=	-0.814

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

ARCA biopharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-7.982	/	14.687
	=	-54.35 %

ARCA biopharma EBIT Related Terms

Thank you for viewing the detailed overview of ARCA biopharma's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

ARCA biopharma (ARCA biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARCA biopharma Inc (NAS:ABIO) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

HQ10:Germany

Address

10170 Church Ranch Way, Suite 100, Westminster, CO, USA, 80021

Website

http://www.arcabiopharma.com

ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.

Executives

James P Flynn	director	41 HARRIS CT, DANVILLE CA 94526
Funicular Funds, Lp	10 percent owner, other: See Footnote 1	2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Funicular Fund, Lp	other: See Footnote 1	2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Jacob Ma-weaver	other: See Remarks	2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Christopher David Ozeroff	officer: S.V.P., General Counsel	8001 ARISTA PLACE, SUITE 200, BROOMFIELD CO 80021
Robert E Conway	director	C/O ARCA BIOPHARMA, INC, 8001 ARISTA PLACE, STE 430, BROOMFIELD CO 80021
C. Jeffrey Dekker	officer: Chief Financial Officer	10170 CHURCH RANCH WAY, WESTMINSTER CO 80021
Thomas A Keuer	officer: Chief Operating Officer	C/O ARCA BIOPHARMA, INC., 10170 CHURCH RANCH WAY, STE 100, WESTMINSTER CO 80021
Brian L. Selby	officer: VP, Finance	11080 CIRCLEPOINT ROAD, SUITE 140, WESTMINSTER CO 80020
Venrock Healthcare Capital Partners Lp	10 percent owner	530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Scott D Sandell	10 percent owner
David M Mott	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Joshua Makower	10 percent owner	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Forest Baskett	10 percent owner
Peter J Barris	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202